Viatris says wins summary judgment in New York securities class action

Viatris announced that the U.S. District Court for the Southern District of New York has dismissed all claims against the company in their entirety and granted its motion for summary judgment in the securities class action related to the company’s marketing, pricing, and classification of EpiPen, as well as alleged conduct concerning generic drug price fixing and market allocation. "The decision addressed all pending claims against all defendants. The company is pleased that the court agreed with its long-standing position that plaintiffs’ securities claims, as well as the allegations relating to the marketing, pricing and classification of EpiPen and alleged conduct concerning generic drug pricing on which those securities claims were based, lacked both factual and legal bases," Viatris stated in a press release.